Axovan Sciences (AXON) bought a drug from GSK in Dec/2014 for $5 million dollars & royalties. The drug was ineffective when used on its own & showed minimal benefits when combined with Aricept for the treatment of Alzheimers. AXON plans to run a Phase III trial combining GSK's drug with Aricept.
They just raised $315 million by selling 21 million shares @ $15.
Who buys this junk? The stock will probably double when it starts trading.
A Look at History: Fed Rate Cycles and Equity Markets
Many investors believe that when rates rise, the party is over for stock prices. Historically, however, this has not been the case.
Consider the past six rate hike cycles going back to the early 1980s. Using time periods of 250 trading days (roughly equivalent to one year), we found that while pockets of weakness surrounded rate hikes, equities generally weathered the storm. In most cases, equities performed well prior to Fed rate increases, then struggled or declined slightly after the onset of rate hikes, only to recover and outperform in the two years following the first rate increase.
Yahoo's best feature is the ignore button. I don't know why everyone doesn't have him on ignore.
You can easily look back at his posts. A number of them say over 200K. Why wouldn't I believe him?
"whogo70 • Feb 7, 2015 2:27 PM Remove 2users liked this postsusers disliked this posts12Reply
My prediction for a secondary.
ATRS will release positive Phase 3 data from the QST trial in the 2nd qtr & use that momentum to raise cash before June/2015"
So in February I was predicting a secondary but how many others on the board thought the same thing? You want me to go away but at least I bring a sense of reality to the board.
Nope, I sold at $2.37 friday. I knew I was going to sell once I saw the special bonus package & yesterdays move was all I needed. I think the stock will continue to trend higher but I'd rather place my money with a different management team.
Your smoking crack if you think Otrexup will ever achieve $200 million in sales. Wotten was fired for being a sleaze & Jefferies just handled the secondary so anything they say should be taken with a grain of salt. $100 million would be a huge achievement.
The stock could go lower since the market is comprised of a bunch of scared idiots. SO credit rating & divy are stable & anyone who says differently doesn't know the facts.
How many times do you have to be proven wrong? Fickenscher just stated he didn't expect to hear anything regarding the CP. He stated that for a reason which was probably to let investors know they were wrong to think we would hear something on the 15th.
the point I'm making.
Read the paragraph again:
As an example: "While it must respond within 180 days, the FDA does not have to respond to a citizen
petition before it rules on a related ANDA. 7 The FDA’s policy is to assess a citizen petition
prior to approving a related ANDA, but the agency does not always issue its formal response to
the petition before ruling on the ANDA. 8 Instead, the FDA often responds to a citizen petition at
the same time it approves an ANDA. As a result of the FDA’s simultaneous review of citizen
petitions and ANDAs, the receipt of a citizen petition may lead the FDA to increase its review
time for an ANDA, especially if the petition raises questions as to the bioequivalence or safety of
the generic drug that is the subject of the ANDA"
I think the 150 - 180 days doesn't matter if the Citizens Petition doesn't delay the approval. The FDA is still reviewing the epi-pen ANDA so the CP isn't impacting the approval timeline. I don't have the time to find the reference I cited from which maybe able to explain it better.
The paragraph I cited was before the 180 days was changed to 150 but it still pertains. I doubt Nammuang can understand the concept that nothing is as clear as it seems on first look. There is always the possibility we get a decision on the CP on the 21st & an approval on the 22nd.
Are these guys nuts? They get an annual bonus based on meeting certain goals. You don't need a special bonus & its another slap in the face of investors.